

July 18, 2023

The Manager- Listing

BSE Limited

Corporate Relationship Dept., 5th Floor, New Trading Ring
Rotunda Building, P J Towers, Dalal Street, Fort,
Mumbai – 400 001

The Manager- Listing

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No. C/1, G Block
Bandra – Kurla Complex, Bandra (E),
Mumbai – 400 051

Dear Sir(s),

Subject: Communication to the shareholders w.r.t. TDS on Dividend

Pursuant to the recommendation of the Dividend by the Board of Directors of the Company at its meeting held on May 30, 2023, the Company has sent the enclosed e-mail communication to its shareholders, with respect to the deduction of tax at source on Dividend for the financial year 2022-23, whose email addresses are registered with the Company/ Depository Participants.

The specimen of the communication is appended herewith for your reference and records, and the same will also be available on the website of the Company at www.astrazeneca.com/india.

We request you to kindly take the above on records.

Thanking you,
Your faithfully,

For **AstraZeneca Pharma India Limited**

Manasa. R
Company Secretary



AstraZeneca Pharma India Limited

Block N1, 12th Floor, Manyata Embassy Business Park
Rachenahalli, Outer Ring Road, Bangalore – 560 045

CIN: L24231KA1979PLC003563

Phone: + 91 – 80- 67748000

Email: comp.secy@astrazeneca.com

Website: www.astrazeneca.com/india

Subject: Deduction of tax at source with respect to Final Dividend recommended (subject to approval of shareholders at the 44th Annual General Meeting).

Dear Shareholders,

FOLIO/DPID & CLIENT ID : _____
NAME OF THE SHAREHOLDER : _____

We hope you are safe and doing well.

As you may be aware that the Board of Directors of your Company have recommended a Final dividend of Rs. 16 per share for the financial year 2022-23 at its meeting held on 30th May 2023, subject to the approval of the shareholders at the ensuing 44th Annual General meeting. The Company has fixed 14th July 2023 as the record date for determining entitlement of members to receive final dividend.

There has been changes introduced under the Income-tax Act, 1961 ('the Act'), pursuant to such amendments dividend income will be taxable in the hands of the shareholders w.e.f. 1 April 2020 and the Company therefore is required to deduct TDS from dividend paid to members at the prescribed rates in the event a dividend is declared.

This communication provides a brief of the applicable Tax Deduction at Source (TDS) provisions under the Act for Resident and Non-Resident members.

1. For resident members, tax shall be deducted at source under Section 194 of the Act as follows:

Members having valid Permanent Account Number ("PAN")	10% or as notified by the Government of India
Members not having PAN / valid PAN/ Members who have not filed their tax returns for the last two years and are considered as specified person in accordance with section 206AB of the Act	20% or as notified by the Government of India

However, no tax shall be deducted on the dividend payable to resident individuals if-

- i. the total dividend amount to be received during the financial year 2022-23 does not exceed Rs.5,000/.
- ii. the member submits Form 15G (applicable to individual) / Form 15H (applicable to an Individual above the age of 60 years), provided that all the required eligibility conditions

are met. Formats of Form 15G and 15H can be downloaded from <https://www.integratedindia.in/ExemptionFormSubmission.aspx>

KINDLY NOTE THAT ONLY THOSE 15G / 15H FORMS SHALL BE CONSIDERED WHICH ARE FOUND COMPLETE IN ALL RESPECTS AND NO FURTHER OPPORTUNITY FOR RESUBMISSION OF THE FORM(S) WILL BE PROVIDED.

- iii. exemption certificate, if any, issued by the Income-tax Department.
- iv. In case of resident non-individual members, no TDS shall be deducted on submission of the following documents:
 - **Insurance companies:** No TDS is required to be deducted as per section 194 of the Act subject to specified conditions. In this regard, we require Self-attested copy of valid IRDA registration certificate and a declaration that it has full beneficial interest with respect to the shares owned by it in the Company.
 - **Category I and II AIF registered with SEBI:** No TDS is required to be deducted as per section 197A(1F) of the Act subject to specified conditions. In this regard, we require self-attested copy of valid SEBI registration certificate and a declaration that they are governed by SEBI regulations as Category I or Category II AIF and its income is exempt under section 10(23FBA) of the Act.
 - **New Pension System Trust:** No TDS is required to be deducted as per section 197A(1E) of the Act subject to specified conditions. In this regard, we require a declaration that shareholder is governed by the provisions of section 10(44) of the Act and therefore no TDS is required to be deducted under section 197(1E) of the Act.
 - **Provident Fund, Superannuation Fund, Gratuity Fund, Pension Fund and ESI Fund** whose income is exempt under section 10 of the Act and on which TDS is not required to be deducted, are required to provide self-attested valid documentary evidence (like approval granted by Income Tax Officer / Commissioner, relevant copy of registration, etc.)

2. For Non-resident Members:

For Non-Resident shareholders, taxes are required to be withheld in accordance with the provisions of Section 195 and other applicable sections of the Act, at the rates in force. The withholding tax shall be at the rate of 20% (plus applicable surcharge and cess) or as notified by Government of India on the amount of dividend payable. However, as per Section 90 of the Act, non-resident shareholders may have an option to be governed by the provisions of the Double Tax Avoidance Treaty (DTAA) between India and the country of tax residence of the shareholder, if they are more beneficial to them. In order to avail the benefits of DTAA, the non-resident shareholders will have to provide the following:

- Self-attested Tax Residency Certificate (TRC) for the financial year 2023-24, obtained from the tax authorities of the country of which the shareholder is a resident.
- Self-attested copy of PAN allotted by the Indian Income Tax authorities. In case of nonavailability of PAN, information under sub-rule 2 of Rule 37BC to be submitted.
- Self-declaration in Form 10F duly filled and signed (Refer Annexure 5).
- Self-declaration from non-resident shareholder, primarily covering the following:
 - Non-resident is and will continue to remain a tax resident of the country of residence during the financial year 2022-23
 - Non-resident is eligible to claim the benefit of respective tax treaty
 - Non-resident has no reason to believe that its claim for the benefits of the DTAA is impaired in any manner
 - Non-resident receiving the dividend income is the beneficial owner of such income
 - Dividend income is not attributable/effectively connected to any permanent establishment (PE) or fixed base in India
 - In case of Foreign Institutional Investors and Foreign Portfolio Investors, self-attested copy of SEBI registration certificate; and

- In case of shareholder being tax resident of Singapore, please furnish the letter issued by the competent authority or any other evidences demonstrating the non-applicability of Article 24 - Limitation of Relief under India-Singapore DoubleTaxation Avoidance Agreement (DTAA).
- Any other documents as prescribed under the Act for lower withholding tax if applicable, duly attested by the shareholder.

The company is not obligated to apply the beneficial DTAA rates at the time of tax deduction/ withholding on dividend amounts. Application of beneficial DTAA rate shall depend upon the completeness and satisfactory review by the company, of the documents submitted by non-resident member.

3. Other general information for the Members

- For all self-attested documents, Members must mention on the document "certified true copy of the original". For all documents being sent/ accepted by email, the Member undertakes to send the original document/s on the request by the Company.
- The aforementioned documents are required to be uploaded on the website <https://www.integratedindia.in/ExemptionFormSubmission.aspx> on or before **Friday, 28th July 2023** in order to enable the company to determine and deduct appropriate TDS/withholding tax. Incomplete and/or unsigned forms and declarations will not be considered by the company. No communication on the tax determination/deduction shall be considered post **28th July 2023**.
- For withholding of tax, residential status of the shareholder will be considered as per the data available with the Company/ the RTA/ the DPs. In case there is any change in the residential status, the shareholders are requested to update their current status with the Company/ the RTA/ the DPs.
- The company will arrange to e-mail a soft copy of TDS certificate at the members' registered e-mail ID in due course, post payment of the said final dividend.
- All communications/queries in this respect should be addressed to our RTA, Integrated Registry Management Services Private Limited at their e-mail ID: giri@integratedindia.in
- Members may note that in case the tax on said dividend is deducted at a higher rate in absence of receipt of the aforementioned details/ documents, option is available to the member to file the return of income as per the Act and claim an appropriate refund, if eligible.
- In the event of any income tax demand (including interest, penalty, etc.) arising from any misrepresentation, inaccuracy or omission of information provided / to be provided by the Member/s, such Member/s will be responsible to indemnify the Company and also, provide the Company with all information / documents and co-operation in any appellate proceedings.

Above communication on TDS only sets out the provisions of law in a summarized manner and does not purport to be a complete analysis or listing of all potential tax consequences. Members should consult their own tax advisors for the tax provisions applicable to their particular circumstances.

AstraZeneca Pharma India Limited

Block N1, 12th Floor,
Manyata Embassy Business Park
Rachenahalli, Outer Ring Road,
Bangalore – 560 045

CIN: L24231KA1979PLC003563

Phone: + 91 – 80- 67748000

Email: comp.secy@astrazeneca.com

Website: www.astrazeneca.com/india